Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiovascular chemotherapy: anticoagulants

J A Shafer1

  • 1Merck Research Laboratories, West Point, PA 19486, USA. Jules_Shafer@Merck.com

Current Opinion in Chemical Biology
|September 16, 1998
PubMed
Summary

Anticoagulant therapy has evolved, with low molecular weight heparin replacing unfractionated heparin and warfarin use increasing for stroke prevention. Effective warfarin administration requires monitoring, not fixed doses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution.

Leukemia & lymphoma·2010
Same author

The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain.

The Journal of biological chemistry·2001
Same author

Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1.

Nature·2000
Same author

Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state.

Proceedings of the National Academy of Sciences of the United States of America·2000
Same author

Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans.

The Journal of biological chemistry·1999
Same author

Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.

The Journal of pharmacology and experimental therapeutics·1999

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Anticoagulant therapy has undergone significant advancements.
  • Low molecular weight heparin (LMWH) is now preferred over unfractionated heparin for parenteral anticoagulation.
  • Warfarin use has risen, particularly for stroke prevention in atrial fibrillation patients.

Purpose of the Study:

  • To review recent changes in anticoagulant therapy.
  • To highlight the efficacy and administration requirements of new anticoagulant agents.

Main Methods:

  • Review of recent clinical practice and research in anticoagulation.
  • Analysis of the role of warfarin, LMWH, and novel oral anticoagulants.

Main Results:

  • LMWH has largely replaced unfractionated heparin.
  • Warfarin requires careful monitoring for effective use, challenging fixed-dose regimens.
  • Parenteral direct thrombin inhibitors like desirudin show efficacy in deep vein thrombosis prevention.
  • Development of oral direct thrombin and factor Xa inhibitors is ongoing.

Conclusions:

  • Modern anticoagulant therapy involves a shift towards LMWH and carefully monitored warfarin.
  • Emerging direct thrombin and factor Xa inhibitors offer new therapeutic options.

Related Experiment Videos